Translational Research
Volume 152, Issue 6 , Pages 257-264 , December 2008

Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection

Received 17 July 2008 ,Revised 24 September 2008 ,Accepted 6 October 2008.

References 

  1. Rello J, Ausina V, Ricart M, Castella J, Prats G. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest. 1993;104:1230–1235
  2. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother. 2007;51:3568–3573
  3. Rello J, Jubert P, Valles J, Artigas A, Rue M, Niederman MS. Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis. 1996;23:973–978
  4. Feldman M, Bryan R, Rajan S, et al. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect Immun. 1998;66:43–51
  5. Ohama M, Hiramatsu K, Miyajima Y, Kishi K, Nasu M, Kadota J. Intratracheal immunization with pili protein protects against mortality associated with Pseudomonas aeruginosa pneumonia in mice. FEMS Immunol Med Microbiol. 2006;47:107–115
  6. Tateda K, Ishii Y, Horikawa M, et al. The Pseudomonas aeruginosa autoinducer N-3-oxododecanoyl homoserine lactone accelerates apoptosis in macrophages and neutrophils. Infect Immun. 2003;71:5785–5793
  7. O'Malley YQ, Abdalla MY, McCormick ML, Reszka KJ, Denning GM, Britigan BE. Subcellular localization of Pseudomonas pyocyanin cytotoxicity in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2003;284:L420–L430
  8. Meyer JM, Neely A, Stintzi A, Georges C, Holder IA. Pyoverdin is essential for virulence of Pseudomonas aeruginosa. Infect Immun. 1996;64:518–523
  9. Kurahashi K, Kajikawa O, Sawa T, et al. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest. 1999;104:743–750
  10. Frank DW. The exoenzyme S regulon of Pseudomonas aeruginosa. Mol Microbiol. 1997;26:621–629
  11. Roy-Burman A, Savel RH, Racine S, et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis. 2001;183:1767–1774
  12. Hauser AR, Cobb E, Bodi M, et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med. 2002;30:521–528
  13. Feltman H, Schulert G, Khan S, Jain M, Peterson L, Hauser AR. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology. 2001;147:2659–2669
  14. Barbieri JT, Sun J. Pseudomonas aeruginosa ExoS and ExoT. Rev Physiol Biochem Pharmacol. 2004;152:79–92
  15. Sato H, Frank DW. ExoU is a potent intracellular phospholipase. Mol Microbiol. 2004;53:1279–1290
  16. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr. 1993;122:1–9
  17. Fegan M, Francis P, Hayward AC, Davis GH, Fuerst JA. Phenotypic conversion of Pseudomonas aeruginosa in cystic fibrosis. J Clin Microbiol. 1990;28:1143–1146
  18. Burns JL, Gibson RL, McNamara S, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis. 2001;183:444–452
  19. Smith EE, Buckley DG, Wu Z, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A. 2006;103:8487–8492
  20. Gallant CV, Raivio TL, Olson JC, Woods DE, Storey DG. Pseudomonas aeruginosa cystic fibrosis clinical isolates produce exotoxin A with altered ADP-ribosyltransferase activity and cytotoxicity. Microbiology. 2000;146:1891–1899
  21. De Vos D, De Chial M, Cochez C, et al. Study of pyoverdine type and production by Pseudomonas aeruginosa isolated from cystic fibrosis patients: prevalence of type II pyoverdine isolates and accumulation of pyoverdine-negative mutations. Arch Microbiol. 2001;175:384–388
  22. Lee B, Haagensen JA, Ciofu O, Andersen JB, Hoiby N, Molin S. Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Clin Microbiol. 2005;43:5247–5255
  23. Luzar MA, Thomassen MJ, Montie TC. Flagella and motility alterations in Pseudomonas aeruginosa strains from patients with cystic fibrosis: relationship to patient clinical condition. Infect Immun. 1985;50:577–582
  24. Romling U, Fiedler B, Bosshammer J, Walshaw MJ, Ledson MJ, Hart CA. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Infect Dis. 1994;170:1616–1621
  25. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration. 2006;73:27–33
  26. Jain M, Ramirez D, Seshadri R, et al. Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis. J Clin Microbiol. 2004;42:5229–5237
  27. Kang PJ, Hauser AR, Apodaca G, et al. Identification of Pseudomonas aeruginosa genes required for epithelial cell injury. Mol Microbiol. 1997;24:1249–1262
  28. Thompson Mr BM, Sokol PA, Lile JD, Iglewski BH. Exoenzyme S: an ADP-ribosyltransferase produced by Pseudomonas Aeruginosa. In:  Smulson MST editors. Novel ADP-ribosylation of regulatory enzymes and proteins. Elsevier/North Holland Inc: Amsterdam, the Netherlands; 1980;p. 425–433
  29. Nguyen D, Singh PK. Evolving stealth: genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections. Proc Natl Acad Sci U S A. 2006;103:8305–8306
  30. Schulert GS, Feltman H, Rabin SD, et al. Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis. 2003;188:1695–1706
  31. Imamura Y, Yanagihara K, Fukuda Y, et al. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model. Eur Respir J. 2007;29:965–968

 Supported by the Cystic Fibrosis Foundation Therapeutics, Inc. (to A.R.H.), Grant K02 AI065615 from the National Institutes of Health (to A.R.H.), Grant NHLBI/NCRR 1K12RR017707-02 (to M.J.), and Grant M01 RR-00048 (to M.J.).

PII: S1931-5244(08)00244-2

doi: 10.1016/j.trsl.2008.10.003

Translational Research
Volume 152, Issue 6 , Pages 257-264 , December 2008

Article Tools

* Image Usage & Resolution